Intercept Shares Plummet Following FDA’s Landmark Regulatory Action
Published on 09/13/2025 at 08:27 | Redaktion boerse-global.deIntercept Pharmaceuticals faces a severe market downturn after the biopharma firm initiated a voluntary withdrawal of its key medication, Ocaliva, from the U.S. market. This decisive action came at the direct request of the Food and Drug Administration (FDA), which simultaneously imposed a full clinical hold on all U.S. studies involving the drug’s active ingredient, obeticholic acid. The one-two regulatory punch represents a devastating development for the company.
This market withdrawal is not an isolated incident but the culmination of persistent regulatory concerns. The FDA had previously refused to grant full approval for Ocaliva in November 2024, issuing a Complete Response Letter that cited significant safety issues. Agency officials specifically highlighted an elevated risk of severe liver injury... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
